Advaxis (ADXS) Getting Somewhat Positive Press Coverage, Accern Reports

News articles about Advaxis (NASDAQ:ADXS) have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Advaxis earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.5670170059761 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Advaxis (NASDAQ ADXS) opened at $2.96 on Friday. Advaxis has a 1-year low of $2.71 and a 1-year high of $10.06. The company has a market cap of $121.55, a price-to-earnings ratio of -1.29 and a beta of 1.91.

Advaxis (NASDAQ:ADXS) last issued its quarterly earnings results on Wednesday, December 20th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.02). The business had revenue of $1.76 million during the quarter, compared to the consensus estimate of $3.05 million. Advaxis had a negative return on equity of 114.00% and a negative net margin of 776.63%. equities analysts forecast that Advaxis will post -2.36 EPS for the current year.

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Advaxis in a research note on Monday, September 25th. ValuEngine cut shares of Advaxis from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Advaxis in a report on Wednesday, November 8th.

In other news, CFO Sara Bonstein sold 12,734 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total transaction of $40,621.46. Following the sale, the chief financial officer now owns 244,504 shares of the company’s stock, valued at approximately $779,967.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Robert Petit sold 12,625 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total transaction of $40,273.75. Following the sale, the insider now directly owns 237,265 shares in the company, valued at approximately $756,875.35. The disclosure for this sale can be found here. Insiders have sold a total of 38,192 shares of company stock worth $122,615 over the last three months. 7.21% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: “Advaxis (ADXS) Getting Somewhat Positive Press Coverage, Accern Reports” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2018/01/14/advaxis-adxs-earns-coverage-optimism-score-of-0-10-updated-updated.html.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Insider Buying and Selling by Quarter for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply